Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange for MCI due to Alzheimer's
NCT06234436Phase 1Enrolling by invitation
- Sponsor
- Oslo University Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fresh Frozen Plasma in Alzheimer's disease (AD), sponsored by Oslo University Hospital. Primary endpoint: Adverse events at 4 years. Started Dec 2023; status: enrolling by invitation.
02
Drugs
Fresh Frozen Plasma
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06234436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234436.